Clinical course of untreated thalamic cavernous malformations: hemorrhage risk and neurological outcomes
- PMID: 27834594
- DOI: 10.3171/2016.8.JNS16934
Clinical course of untreated thalamic cavernous malformations: hemorrhage risk and neurological outcomes
Abstract
OBJECTIVE The natural history of cerebral cavernous malformations (CMs) has been widely studied, but the clinical course of untreated thalamic CMs is largely unknown. Hemorrhage of these lesions can be devastating. The authors undertook this study to obtain a prospective hemorrhage rate and provide a better understanding of the prognosis of untreated thalamic CMs. METHODS This longitudinal cohort study included patients with thalamic CMs who were diagnosed between 2000 and 2015. Clinical data were recorded, radiological studies were extensively reviewed, and follow-up evaluations were performed. RESULTS A total of 121 patients were included in the study (56.2% female), with a mean follow-up duration of 3.6 years. The overall annual hemorrhage rate (subsequent to the initial presentation) was calculated to be 9.7% based on the occurrence of 42 hemorrhages over 433.1 patient-years. This rate was highest in patients (n = 87) who initially presented with hemorrhage and focal neurological deficits (FNDs) (14.1%) (χ2 = 15.358, p < 0.001), followed by patients (n = 19) with hemorrhage but without FND (4.5%) and patients (n = 15) without hemorrhage regardless of symptoms (1.2%). The initial patient presentations of hemorrhage with FND (hazard ratio [HR] 2.767, 95% CI 1.336-5.731, p = 0.006) and associated developmental venous anomaly (DVA) (HR 2.510, 95% CI 1.275-4.942, p = 0.008) were identified as independent hemorrhage risk factors. The annual hemorrhage rate was significantly higher in patients with hemorrhagic pres entation at diagnosis (11.7%, p = 0.004) or DVA (15.7%, p = 0.002). Compared with the modified Rankin Scale (mRS) score at diagnosis (mean 2.2), the final mRS score (mean 2.0) was improved in 37 patients (30.6%), stable in 59 patients (48.8%), and worse in 25 patients (20.7%). Lesion size (odds ratio [OR] per 0.1 cm increase 3.410, 95% CI 1.272-9.146, p = 0.015) and mRS score at diagnosis (OR per 1 point increase 3.548, 95% CI 1.815-6.937, p < 0.001) were independent adverse risk factors for poor neurological outcome (mRS score ≥ 2). Patients experiencing hemorrhage after the initial ictus (OR per 1 ictus increase 6.923, 95% CI 3.023-15.855, p < 0.001) had a greater chance of worsened neurological status. CONCLUSIONS This study verified the adverse predictors for hemorrhage and functional outcomes of thalamic CMs and demonstrated an overall annual symptomatic hemorrhage rate of 9.7% after the initial presentation. These findings and the mode of initial presentation are useful for clinicians and patients when selecting an appropriate treatment, although the tertiary referral bias of the series should be taken into account.
Keywords: CCM = cerebral cavernous malformation; CM = cavernous malformation; DVA = developmental venous anomaly; FND = focal neurological deficit; GK = Gamma Knife; HR = hazard ratio; OR = odds ratio; cavernoma; cavernous malformation; mRS = modified Rankin Scale; natural history; thalamus; vascular disorders.
Similar articles
-
Hemorrhage risks and functional outcomes of untreated brainstem cavernous malformations.J Neurosurg. 2014 Jul;121(1):32-41. doi: 10.3171/2014.3.JNS132537. Epub 2014 May 2. J Neurosurg. 2014. PMID: 24785325
-
Natural history of brainstem cavernous malformations: prospective hemorrhage rate and adverse factors in a consecutive prospective cohort.J Neurosurg. 2020 Mar 13;134(3):917-928. doi: 10.3171/2019.12.JNS192856. Print 2021 Mar 1. J Neurosurg. 2020. PMID: 32168479
-
Hemorrhage from cerebral cavernous malformations: a systematic pooled analysis.J Neurosurg. 2017 Apr;126(4):1079-1087. doi: 10.3171/2016.3.JNS152419. Epub 2016 May 20. J Neurosurg. 2017. PMID: 27203143
-
Clinical course of untreated pediatric brainstem cavernous malformations: hemorrhage risk and functional recovery.J Neurosurg Pediatr. 2014 May;13(5):471-83. doi: 10.3171/2014.2.PEDS13487. Epub 2014 Mar 17. J Neurosurg Pediatr. 2014. PMID: 24635136
-
Surgical treatment and long-term outcomes of thalamic cavernous malformations.World Neurosurg. 2013 May-Jun;79(5-6):704-13. doi: 10.1016/j.wneu.2012.01.037. Epub 2012 Jan 26. World Neurosurg. 2013. PMID: 22381871 Review.
Cited by
-
Deep Ganglionic Intracerebral Hemorrhage Due to Cavernous Malformation Mimicking Hypertensive Hemorrhage: A Report of Two Cases.Cureus. 2023 Mar 21;15(3):e36448. doi: 10.7759/cureus.36448. eCollection 2023 Mar. Cureus. 2023. PMID: 37090334 Free PMC article.
-
Natural history of incidentally diagnosed brainstem cavernous malformations in a prospective observational cohort.Neurosurg Rev. 2021 Apr;44(2):1151-1164. doi: 10.1007/s10143-020-01308-0. Epub 2020 May 12. Neurosurg Rev. 2021. PMID: 32399728 Clinical Trial.
-
Occipital Lobe Cavernoma Presenting With Headaches and Visual Hallucinations: A Case Report.Cureus. 2024 Jan 2;16(1):e51506. doi: 10.7759/cureus.51506. eCollection 2024 Jan. Cureus. 2024. PMID: 38304654 Free PMC article.
-
Five-year symptomatic hemorrhage risk of untreated brainstem cavernous malformations in a prospective cohort.Neurosurg Rev. 2022 Aug;45(4):2961-2973. doi: 10.1007/s10143-022-01815-2. Epub 2022 May 28. Neurosurg Rev. 2022. PMID: 35633420
-
Cavernous malformation hemorrhage due to trans-mural pressure alterations after cerebrospinal fluid diversion: a case report.BMC Neurol. 2020 Apr 13;20(1):131. doi: 10.1186/s12883-020-01714-3. BMC Neurol. 2020. PMID: 32284039 Free PMC article.
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical